Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer

Clinical Infectious Diseases

Volumn 32, Issue 1, 2001, Pages 36-43

  Hughes, W T ^a,b   Flynn, P M ^a,b   Baker, D K ^a,b   Hetherington, S V ^a,b,c   Hudson, M M ^a,b   Patrick, C C ^a,b   Roberson, P K ^a,c   Sandlund, J T ^a,b   Santana, V M ^a,b   Sixbey, J W ^a,b,c   Slobod, K S ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFIXIME; CEFTAZIDIME; TICARCILLIN; TOBRAMYCIN; VANCOMYCIN;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CEFIXIME; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; CONSUMER PRODUCT SAFETY; FEMALE; FEVER; HUMANS; INFANT; INJECTIONS, INTRAVENOUS; MALE; NEOPLASMS; NEUTROPENIA; TREATMENT FAILURE;

EID: 0035130417     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/317552     Document Type: Article

References (31)

1. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia
2. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer
3. Early hospital discharge of children with cancer treated for fever and neutropenia: Identification and management of the low-risk patient
4. Hematologic predictors of bone marrow recovery in neutropenic patients hospitalized for fever: Implications for discontinuation of antibiotics and early discharge from the hospital
5. Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia
6. Risk factors for recurrent fever after the discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic condition
7. Discontinuation of intravenous antibiotic therapy during persistent neutropenia in patients receiving prophylaxis with oral ciprofloxacin
8. Safety of early hospital discharge of selected febrile children and adolescents with cancer with prolonged neutropenia
9. Early discharge of low-risk febrile neutropenic children and adolescents with cancer
10. Cessation of antibiotics regardless of ANC is safe in children with febrile neutropenia: A preliminary prospective trial
11. Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: A prospective study
12. The pharmacokinetic and bactericidal characteristics of oral cefixime
13. In vitro evaluation of cefixime (FK027, FR17027, CL284635): Spectrum against recent clinical isolates, comparative antimicrobial activity,β-lactamase stability, and preliminary susceptibility, testing criteria
14. Bowel flora changes in humans receiving cefixime (CL 284,635) or cefaclor
15. In vitro comparison of activity of cefixime with activities of other orally administered antimicrobial agents
16. How many stratification factors are "too many" to use in a randomized plan?
17. Cefixime: A new oral cephalosporin
18. A multiple testing procedure for clinical trials
19. Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer
20. In situ management of confirmed central venous catheter-related bacteremia
21. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever
22. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy
23. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy
24. Randomized comparison of oral ofloxacin alone with combination of parenteral antibioitics in neutropenic febrile patients
25. Oral ciprofloxacin vs. Intravenous ceftriaxone administered in an out-patient setting for fever and neutropenia in low-risk pediatric oncology patients: Randomized prospective trial
26. Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer
27. Post-sepsis prophylaxis in cancer patients
28. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis
29. Combination and single-agent empirical antibacterial therapy for febrile cancer patients with neutropenia and mucositis
30. Early discharge of pediatric febrile neutropenic cancer patients by substitution of oral for intravenous antibiotics
31. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer